
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci is well-positioned for success due to its innovative platform that integrates generative AI and high-throughput biology to design novel protein therapeutics. With a lead product candidate, ABS-201, in phase 1/2a for Pattern Hair Loss and promising results in non-human clinical trials, Absci has potential for strong sales growth in the PHL and endometriosis markets. However, competition in these markets and reliance on third-party suppliers for manufacturing are potential risks that could impact the company's success.
Bears say
Absci is a promising but risky investment opportunity, as its leading drug candidate ABS-201 shows potential in treating endometriosis and alopecia through its unique discovery approach and promising clinical results, but the company is still in the development stage and the cause of endometriosis is not fully understood.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares